The clinical research of Otilonium Bromide and Mesalazine extended release tablets on ulcerative colitis

Objective To investigate the clinical efficacy,adverse effects and the half year relapse rate of Otilonium Bromide and Mesalazine extended release tablets on patients of ulcerative colitis. Methods Patients were randomly divided into the treatment group(36 cases) and control group(32 cases).The patients in treatment group were treated by Otilonium Bromide 40mg,three times daily and Mesalazine extended release tablets 100mg,three times daily after meals,while the patients in control group by Mesalazine extended release tablets100mg,three times daily after meals,with a treatment course of 4 weeks for both groups,After 4 weeks,the hepatic function,immunoglobulin,3 kinds of conventional detections and enteroscope were reviewed and followed-up for 6 months. Results The effectual rate in treatment group and control group were 47.2% and 34.3%.Total effective rate in treatment group and control group were 86.1% and 71.9%,while the half year relapse rate were 16.7% and 34.4%,the main side effects were mild leukocytopenia(2 cases,6.3%),mild gastrointestinal reactions(8 cases,25%). Conclusion Otilonium Bromide and Mesalazine extended release tablets have good treatment effect on ulcerative colitis with less adverse effects and lower half year relapse rate,it is better than Mesalazine extended release tablets.